Solid Biosciences (SLDB) Stock Price, News & Analysis

-0.34 (-3.73%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
138,410 shs
Average Volume
212,171 shs
Market Capitalization
$331.77 million
P/E Ratio
Dividend Yield
Price Target

Solid Biosciences MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
108.1% Upside
$18.25 Price Target
Short Interest
3.05% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Selling Shares
$1,111 Sold Last Quarter
Proj. Earnings Growth
From ($2.64) to ($2.48) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.66 out of 5 stars

Medical Sector

239th out of 907 stocks

Biological Products, Except Diagnostic Industry

35th out of 153 stocks

SLDB stock logo

About Solid Biosciences Stock (NASDAQ:SLDB)

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

SLDB Stock Price History

SLDB Stock News Headlines

How to camouflage a factory of 53,000 workers
"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."
How to camouflage a factory of 53,000 workers
"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."
SLDB Apr 2024 7.500 put
Solid Biosciences (SLDB) Gets a Buy from Barclays
SLDB Sep 2024 17.500 call
Solid Biosciences Stock Drops 4% Due To Wider Loss In Q4
Leerink Partners Keeps Their Hold Rating on Solid Biosciences (SLDB)
SLDB Mar 2024 10.000 put
See More Headlines
Receive SLDB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Solid Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$8.09 million
Book Value
$6.27 per share


Free Float
Market Cap
$331.77 million
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Ian F. Smith A.C.A. (Age 58)
    C.P.A., Executive Chair
    Comp: $75k
  • Mr. Alexander G. Cumbo (Age 53)
    President, CEO & Director
    Comp: $1.82M
  • Mr. Ilan Ganot (Age 50)
    Co-founder, Strategic Advisor to the CEO & Director
    Comp: $1.36M
  • Mr. David Tyronne Howton Jr. (Age 52)
    J.D., COO & Secretary
    Comp: $1.4M
  • Mr. Gilad David Hayeem (Age 56)
  • Ms. Annie Ganot
    Co-Founder & Head of Patient Advocacy
  • Dr. Andrey Juan Zarur Ph.D. (Age 53)
    Comp: $90.17k
  • Mr. Kevin Tan C.F.A. (Age 47)
    CFO & Treasurer
  • Mr. Stephen J. Di Palma M.B.A. (Age 65)
    Treasurer & Principal Accounting Officer
  • Mr. Paul Herzich (Age 46)
    Chief Technology Officer

SLDB Stock Analysis - Frequently Asked Questions

Should I buy or sell Solid Biosciences stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SLDB shares.
View SLDB analyst ratings
or view top-rated stocks.

What is Solid Biosciences' stock price target for 2024?

6 equities research analysts have issued 12-month price objectives for Solid Biosciences' shares. Their SLDB share price targets range from $16.00 to $21.00. On average, they predict the company's share price to reach $18.25 in the next year. This suggests a possible upside of 108.1% from the stock's current price.
View analysts price targets for SLDB
or view top-rated stocks among Wall Street analysts.

How have SLDB shares performed in 2024?

Solid Biosciences' stock was trading at $6.14 at the beginning of 2024. Since then, SLDB stock has increased by 42.8% and is now trading at $8.77.
View the best growth stocks for 2024 here

Are investors shorting Solid Biosciences?

Solid Biosciences saw a increase in short interest in March. As of March 31st, there was short interest totaling 920,900 shares, an increase of 49.8% from the March 15th total of 614,900 shares. Based on an average daily trading volume, of 362,300 shares, the days-to-cover ratio is currently 2.5 days. Currently, 3.1% of the shares of the stock are sold short.
View Solid Biosciences' Short Interest

When is Solid Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our SLDB earnings forecast

How were Solid Biosciences' earnings last quarter?

Solid Biosciences Inc. (NASDAQ:SLDB) announced its earnings results on Wednesday, March, 13th. The company reported ($1.00) EPS for the quarter, beating analysts' consensus estimates of ($1.01) by $0.01.

What ETFs hold Solid Biosciences' stock?

ETFs with the largest weight of Solid Biosciences (NASDAQ:SLDB) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Invesco DWA SmallCap Momentum ETF (DWAS).

When did Solid Biosciences' stock split?

Solid Biosciences's stock reverse split on Friday, October 28th 2022. The 1-15 reverse split was announced on Friday, October 28th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 28th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Solid Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Solid Biosciences investors own include Selecta Biosciences (SELB), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Cidara Therapeutics (CDTX), SCYNEXIS (SCYX), Verastem (VSTM) and Agile Therapeutics (AGRX).

When did Solid Biosciences IPO?

Solid Biosciences (SLDB) raised $130 million in an IPO on Friday, January 26th 2018. The company issued 7,000,000 shares at a price of $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO and Nomura and Chardan were co-managers.

How do I buy shares of Solid Biosciences?

Shares of SLDB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLDB) was last updated on 4/25/2024 by Staff

From Our Partners